Microbiome-mediated therapies for aging and healthspan in marmosets

Information

  • Research Project
  • 10266837
  • ApplicationId
    10266837
  • Core Project Number
    R01AG065546
  • Full Project Number
    5R01AG065546-02
  • Serial Number
    065546
  • FOA Number
    PA-19-056
  • Sub Project Id
  • Project Start Date
    9/30/2020 - 3 years ago
  • Project End Date
    5/31/2025 - 10 months from now
  • Program Officer Name
    FULDNER, REBECCA A
  • Budget Start Date
    6/1/2021 - 3 years ago
  • Budget End Date
    5/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    6/23/2021 - 3 years ago

Microbiome-mediated therapies for aging and healthspan in marmosets

PROJECT SUMMARY The number one complaint given by the elderly is not pain and discomfort, but rather the need for independence as a part of their quality of life. Independence and health are ultimately tied to disease progression and elderly resilience, which may be related to the ability to be stress resistant and to recover following disease onset. The focus of aging research has now shifted to treating aging as a systemic problem, and determining whether an increase in lifespan alters the ability for that individual to remain disease free. The hope is that the treatment for multiple age-related diseases including diabetes, cardiovascular disease, Alzheimer's disease, dementia, and sarcopenia could be discovered by understanding mechanisms that underlie the basic systemic aging process. One potentially unexplored mechanism for age-related changes is the alteration of the intestinal microbiome. Dysbiosis of the microbiome has been associated with Type 2 diabetes, obesity, cardiovascular disease, frailty, aging, and Alzheimer's disease in human populations and may in fact be associated with the aging process. Unfortunately, evaluating dysbiosis in aging human populations is confounded by changes in dietary intake, exposure to pharmaceuticals, and alterations in physical activity. We hypothesize that loss of microbial diversity is significantly associated with the aging process and seek to evaluate these changes in a nonhuman primate model, the common marmoset. Further, we hypothesize that oral fecal microbiota transplants may be a potential therapeutic for stabilizing the aging microbiome and increasing healthspan maintenance. The proposed studies will evaluate the stability of the microbial diversity and function in aging marmosets, and the associated changes in measures of health. Fecal microbiota transplant will be conducted in aged marmosets and longitudinal assessment of microbial diversity and health will allow us to evaluate the efficacy of this treatment as an intervention for human healthspan.

IC Name
NATIONAL INSTITUTE ON AGING
  • Activity
    R01
  • Administering IC
    AG
  • Application Type
    5
  • Direct Cost Amount
    459578
  • Indirect Cost Amount
    298057
  • Total Cost
    757635
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    866
  • Ed Inst. Type
  • Funding ICs
    NIA:757635\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ASG
  • Study Section Name
    Aging Systems and Geriatrics Study Section
  • Organization Name
    TEXAS BIOMEDICAL RESEARCH INSTITUTE
  • Organization Department
  • Organization DUNS
    007936834
  • Organization City
    SAN ANTONIO
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    782275302
  • Organization District
    UNITED STATES